Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium - Wikidata - awgldk - TriplyDB

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium

http://www.wikidata.org/entity/Q30362607

about

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS Lithium: the pharmacodynamic actions of the amazing ion Glycogen synthase kinase 3: more than a namesake Regulation of glycogen synthase kinase-3 during bipolar mania treatment Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics Review of pharmacological treatment in mood disorders and future directions for drug development.Wnt signaling in the vertebrate central nervous system: from axon guidance to synaptic function.Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Wnt signaling in neuropsychiatric disorders: ties with adult hippocampal neurogenesis and behavior Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders Individual Differences in Behavioural Despair Predict Brain GSK-3beta Expression in Mice: The Power of a Modified Swim Test.Wnt signaling networks in autism spectrum disorder and intellectual disability A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited Molecular actions and clinical pharmacogenetics of lithium therapy DISC1: Structure, Function, and Therapeutic Potential for Major Mental Illness Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3 NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy New therapeutic targets for mood disorders Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2 Animal models of bipolar mania: The past, present and future.Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3.Lithium and genetic inhibition of GSK3beta enhance the effect of methamphetamine on circadian rhythms in the mouse Protein Phosphatase 2a and glycogen synthase kinase 3 signaling modulate prepulse inhibition of the acoustic startle response by altering cortical M-Type potassium channel activity Predictive animal models of mania: hits, misses and future directions.Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice.Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes GSK-3: Functional Insights from Cell Biology and Animal Models.Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans.Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.Is glycogen synthase kinase-3 a central modulator in mood regulation?Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects Abnormalities in brain structure and behavior in GSK-3alpha mutant mice Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

P2860

Q21129276-78DEC7C6-23DE-4242-AC86-AC14C01CFE52 Q21129334-A3EB6ABD-A9F7-4F8B-BCFF-E2AF1759B815 Q22241779-EB96C8A9-F451-4328-B08B-0878294E8DF4 Q24315635-27C368AF-4FCF-4E1E-A0BF-CC7ED1BD6BA9 Q24594534-7491228F-9823-4353-A671-1BF203586AD2 Q24626017-7DCDEE68-79F0-4AB6-95B1-A374040464BA Q24651407-F74591F3-541D-47B0-B578-421DF0F30B7B Q24685475-75D7372D-8C35-4266-B6B2-05C926E03473 Q26853509-7588E0B0-4D8C-4DE0-B821-96F71F523B97 Q27000787-189000DE-68AC-47BF-8419-64C0688F31CC Q27004490-45C9AFF5-8BA9-425B-A28B-F8CBE64FF382 Q27008843-6C59FA6F-A3B7-49B9-A62E-B45B4355F36F Q27027115-9CEE2773-E744-431D-B124-70043A2CD463 Q27312769-6F109E49-3A88-401A-BB4F-BC7FD054D809 Q28074740-42024B4A-FDAD-4B92-80D1-549B2FCEA62C Q28118906-E1C96D3A-0D36-4EC1-8CD3-FA4BAC82FA4E Q28251880-FCC4683B-53E4-4E2E-ADFF-8CD3B3885494 Q28294604-7DAFA84B-046A-4DB4-B7C7-177246D517A5 Q28307770-01551BBD-08F7-461E-BE9E-511C68E25163 Q28393891-8F10BC0D-C576-4F5F-9587-113BEC80C746 Q28468536-B243A0E1-18B4-4A73-8D2D-11AE03EF5933 Q28567705-678CB67A-D282-4C04-B8D3-EED7E3285F56 Q28586033-D278CB16-ACA2-4860-A934-899A09CC144A Q28743068-BC0A380B-41E5-4B88-BF00-9532DB02D402 Q28943444-13BCD958-D4AC-4CEA-9106-A6DD0627160F Q30357298-8BCF279D-9081-4829-8B71-E983FC40C868 Q30408186-D8E6AF62-B651-4779-862E-1A6AFE9AF449 Q30435752-9AF1DA65-A7D7-4C2A-8287-30A2016E11ED Q30445781-068A5CBB-3DA0-4085-AD8D-18F611D3E23E Q30462823-0A535505-B7FB-4F92-8027-44361C7B227F Q30464459-EFF8697F-8118-4620-B35E-09B1608E198C Q30465622-76790A63-402A-46F2-8DB4-E607B5FBD0AA Q30468815-E8058A8B-3159-45DB-879E-3E3ABC295A50 Q30472813-97C70C6F-9E57-4FFA-89CD-D32DD55C58D6 Q30473236-F7FDC628-F45D-4597-8CDD-5C44059B83E5 Q30474415-1CCADEA6-9984-4B9F-A944-4FC19C8C1D54 Q30475816-096FCE53-F4F4-4967-BEDA-63864B24AE86 Q30476813-74A1CD57-F962-42CC-8098-BE076BF0FB3D Q30485018-880BDFA2-E3E3-4209-9280-ABBF6AD7363E Q30488395-4B2D0347-D72C-4F21-8E70-60552270D55D

P2860

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium

http://www.wikidata.org/entity/Q30362607

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Glycogen synthase kinase-3beta ...... d molecular effects of lithium

@ast

Glycogen synthase kinase-3beta ...... d molecular effects of lithium

@en

type

label

Glycogen synthase kinase-3beta ...... d molecular effects of lithium

@ast

Glycogen synthase kinase-3beta ...... d molecular effects of lithium

@en

prefLabel

Glycogen synthase kinase-3beta ...... d molecular effects of lithium

@ast

Glycogen synthase kinase-3beta ...... d molecular effects of lithium

@en

P1433

Q30362607-001AACF8-18D9-48CB-A1C9-DD64EF00D4B6

P1476

Q30362607-C55834CC-EDB3-4B75-BE91-DA3A38441B54

P2093

Q30362607-087C1426-6A3F-403C-8882-E20D5B9822D7

Q30362607-15C2500A-0B14-4707-B2FE-4B1B6A98D0F3

Q30362607-4EEFE2F7-E8D9-42EB-812C-5A5DD0198958

Q30362607-84991711-96D7-4917-B471-66E6E3168B61

Q30362607-BE0087C7-C7F0-4BF7-ACE6-B7660A2B2232

Q30362607-DABA2C1B-D3AF-4903-B6E2-8278D1660FAA

P2860

Q30362607-02D5D3EB-26C9-4A9A-B333-A129CF7B6120

Q30362607-042F9EA7-5F18-4EBD-9266-7964882BB608

Q30362607-0C684D43-D656-49C2-9D02-219E1C483A99

Q30362607-10F1E9C1-42FB-4B06-8288-B16C0D3B48FB

Q30362607-1499F069-333A-4172-B2B2-043423CC1F18

Q30362607-14C8AA12-70EF-431E-B6C4-0FC3078DB9E6

Q30362607-19F968AB-5157-4089-8256-DDFB5C69090B

Q30362607-1CBA9C5D-A8C4-448E-B68B-E90BF24DEE20

Q30362607-28C196D6-7CF1-43EC-A917-A262BC28F0B1

Q30362607-2DE5538A-3FC5-4842-9532-555D582F9ACF

P304

Q30362607-B66B5EEF-0D8B-44AD-91B5-2B39E1E44C7A

P31

Q30362607-73AA890E-68C3-48FE-8964-9088B6AC8152

P356

Q30362607-36076F36-1389-49E3-AD91-36978FDF7C37

P407

Q30362607-705A7330-01BD-444C-BCFB-44DF7F71A244

P433

Q30362607-D165811F-7B36-495F-8486-139FAC505641

P478

Q30362607-21006A8E-301B-46E0-AD1A-7D96843D0241

P50

Q30362607-E1C5969B-6E65-4A18-A957-41CC20B7849B

P577

Q30362607-0B3E3511-8AA7-4ECF-BB4D-C20E4F40A7A4

P698

Q30362607-35AE83AA-C2CC-410F-A3DC-EDF396A23484

P921

Q30362607-AE2B762E-F66C-49A5-A613-396E317B8787

P932

Q30362607-B309BD17-1E4B-44CF-8AE0-F9F85A3753EB

P356

JNEUROSCI.4753-03.2004

P1433

Journal of Neuroscience

P1476

Glycogen synthase kinase-3beta ...... d molecular effects of lithium

@en

P2093

Amber DeAra Harper

http://www.w3.org/2001/XMLSchema#string

Fernando Jové

http://www.w3.org/2001/XMLSchema#string

Peter S Klein

http://www.w3.org/2001/XMLSchema#string

Silvia Maretto

http://www.w3.org/2001/XMLSchema#string

Stefano Piccolo

http://www.w3.org/2001/XMLSchema#string

W Timothy O'Brien

http://www.w3.org/2001/XMLSchema#string

P2860

GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis

Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure

A molecular mechanism for the effect of lithium on development

beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex

GSK-3-selective inhibitors derived from Tyrian purple indirubins

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

Neural and developmental actions of lithium: a unifying hypothesis

Behavioral despair in mice: a primary screening test for antidepressants

Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium

P304

6791-6798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.4753-03.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

James R. Woodgett

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15282284

http://www.w3.org/2001/XMLSchema#string

P921

haploinsufficiency

P932

5328671

http://www.w3.org/2001/XMLSchema#string